OSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
- Conditions
- Carcinoma, Non-small-cell Lung
- Registration Number
- NCT00036647
- Lead Sponsor
- OSI Pharmaceuticals
- Brief Summary
The purpose of this study is to determine if OSI-774 will improve overall survival of patients with incurable stage IIIB/IV non-small cell lung cancer compared to standard of care. OSI-774 is a new type of drug under evaluation called an epidermal growth factor receptor (EGFR). OSI-774 is an investigational drug that has not yet been approved by the U.S. Food and Drug Administration (FDA).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 731
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (96)
University of Chicago Medical Center
🇺🇸Chicago, Illinois, United States
University of Washington
🇺🇸Seattle, Washington, United States
Centro Medico Confidence
🇦🇷Buenos Aires, CP, Argentina
Hospital Britanico
🇦🇷Buenos Aires, Argentina
Hospital Interzonal de Agudos Evita
🇦🇷Buenos Aires, Argentina
Instituto Alexander fleming
🇦🇷Buenos Aires, Argentina
Hospital Churruca Visca
🇦🇷Buenos Aires, Argentina
Instituto Oncologico Angel Roffo
🇦🇷Capital Federal, Argentina
Hospital Italiano
🇦🇷Capital Federal, Argentina
Canberra Hospital- Australia
🇦🇺Woden, Australian Capital Territory, Australia
Scroll for more (86 remaining)University of Chicago Medical Center🇺🇸Chicago, Illinois, United States